CA3131312A1 - Treatment with p2x3 modulators - Google Patents

Treatment with p2x3 modulators Download PDF

Info

Publication number
CA3131312A1
CA3131312A1 CA3131312A CA3131312A CA3131312A1 CA 3131312 A1 CA3131312 A1 CA 3131312A1 CA 3131312 A CA3131312 A CA 3131312A CA 3131312 A CA3131312 A CA 3131312A CA 3131312 A1 CA3131312 A1 CA 3131312A1
Authority
CA
Canada
Prior art keywords
compound
antagonist
alkyl
hydrogen
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3131312A
Other languages
English (en)
French (fr)
Inventor
Antonios Matzouranis
Denis Garceau
Roberto Bellini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 3 Ltd
Original Assignee
Bellus Health Cough Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bellus Health Cough Inc filed Critical Bellus Health Cough Inc
Publication of CA3131312A1 publication Critical patent/CA3131312A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3131312A 2019-02-25 2020-02-24 Treatment with p2x3 modulators Pending CA3131312A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962810163P 2019-02-25 2019-02-25
US62/810,163 2019-02-25
PCT/IB2020/000160 WO2020174283A1 (en) 2019-02-25 2020-02-24 Treatment with p2x3 modulators

Publications (1)

Publication Number Publication Date
CA3131312A1 true CA3131312A1 (en) 2020-09-03

Family

ID=72239247

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3131312A Pending CA3131312A1 (en) 2019-02-25 2020-02-24 Treatment with p2x3 modulators

Country Status (8)

Country Link
US (1) US12485125B2 (enExample)
EP (1) EP3930722A4 (enExample)
JP (1) JP7578602B2 (enExample)
CN (1) CN113727716A (enExample)
AU (1) AU2020228760A1 (enExample)
CA (1) CA3131312A1 (enExample)
IL (1) IL285772A (enExample)
WO (1) WO2020174283A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3930722A4 (en) 2019-02-25 2022-12-28 Bellus Health Cough Inc. TREATMENT WITH P2X3 MODULATORS
IL295393A (en) * 2020-02-14 2022-10-01 Bellus Health Cough Inc P2x3 modulators
CN113754654A (zh) * 2020-06-05 2021-12-07 武汉人福创新药物研发中心有限公司 咪唑并吡啶类化合物及其用途
CN116635389A (zh) * 2021-01-29 2023-08-22 上海海雁医药科技有限公司 吗啉衍生物及其药物组合物和用途
CN115043836B (zh) * 2021-08-20 2023-07-18 苏州璞正医药有限公司 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途
GB202212749D0 (en) * 2022-09-01 2022-10-19 Gesynta Pharma Ab New uses

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH503559A (de) 1969-02-26 1971-02-28 Arx Paul Von Vorrichtung an Tafelschere zum Schneiden nach Markierungen, unter ständiger Beobachtung des Schnittes
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
PL194689B1 (pl) 1996-02-13 2007-06-29 Astrazeneca Uk Ltd Pochodne chinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania
EP0885198B1 (en) 1996-03-05 2001-12-19 AstraZeneca AB 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
TR200500745T2 (tr) 1999-02-10 2005-05-23 Astrazeneca Ab Damar gelişimi inhibitörleri olarak kuinazolin türevleri.
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
WO2002008213A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
WO2002085309A2 (en) 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Composition, formulations & kits for treatment of respiratory & lung disease with anti-sense oligonucleotides & a bronchodilating agent
SE0102808D0 (sv) 2001-08-22 2001-08-22 Astrazeneca Ab New compounds
JP2004002826A (ja) 2002-04-24 2004-01-08 Sankyo Co Ltd 高分子イミダゾピリジン誘導体
BRPI0515897A (pt) 2004-09-24 2008-08-12 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto
US7745451B2 (en) 2005-05-04 2010-06-29 Renovis, Inc. Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and dysfunctions
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
JP5608655B2 (ja) 2008-09-18 2014-10-15 エヴォテック アーゲー Ｐ２ｘ３受容体活性のモジュレーター
RU2542582C2 (ru) * 2009-11-18 2015-02-20 Астразенека Аб Производные бензимидазола, полезные при лечении состояний, ассоциированных с активностью р2х3 или р2х2/3
WO2012158117A1 (en) * 2011-05-17 2012-11-22 Astrazeneca Ab Combination therapies for treating pain
US9526718B2 (en) 2011-06-28 2016-12-27 Vivozon, Inc. Combination of effective substances causing synergistic effects of multiple targeting and use thereof
KR102120513B1 (ko) 2013-01-31 2020-06-08 네오메드 인스티튜트 이미다조피리딘 화합물 및 이의 용도
US9937815B2 (en) 2013-08-15 2018-04-10 Volvo Truck Corporation Method and arrangement for balancing an energy storage system
MX367657B (es) 2013-08-23 2019-08-30 Afferent Pharmaceuticals Inc Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica.
DK3587417T3 (da) * 2014-12-09 2022-03-28 Bayer Ag 1,3-thiazol-2-yl-substituerede benzamider
WO2017058645A1 (en) 2015-09-29 2017-04-06 Afferent Pharmaceuticals, Inc. Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough
US9907795B2 (en) * 2016-01-08 2018-03-06 Nerre Therapeutics Limited Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents
EP3430000B1 (en) 2016-03-14 2022-12-28 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
EP3528813B1 (en) 2016-09-30 2025-04-16 ABS Development 1, Inc. P2x3 and/or p2x2/3 compounds and methods
US10111883B1 (en) 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
CN108904507A (zh) * 2018-02-11 2018-11-30 赖英杰 P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用
HUE071480T2 (hu) * 2018-11-13 2025-08-28 Glaxosmithkline Intellectual Property No 3 A P2X3-modulátor metil (S)-2-((2-(2,6-difluoro-4-(metil-karbamoil)fenil)-7-metilimidazo[1,2-a] piridin-3-il)metil)morfolin-4-karboxilát kristályos formái
WO2020112890A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith
AU2019416589B2 (en) 2018-12-29 2023-04-06 Wuhan Ll Science And Technology Development Co., Ltd. Heterocyclic compound intermediate, preparation method therefor and application thereof
EP3930722A4 (en) 2019-02-25 2022-12-28 Bellus Health Cough Inc. TREATMENT WITH P2X3 MODULATORS
IL295393A (en) 2020-02-14 2022-10-01 Bellus Health Cough Inc P2x3 modulators
US20230101612A1 (en) 2020-02-14 2023-03-30 Bellus Health Cough Inc. Preparation of a p2x3 antagonist

Also Published As

Publication number Publication date
IL285772A (en) 2021-10-31
US20210386751A1 (en) 2021-12-16
WO2020174283A1 (en) 2020-09-03
US12485125B2 (en) 2025-12-02
CN113727716A (zh) 2021-11-30
AU2020228760A1 (en) 2021-09-23
EP3930722A1 (en) 2022-01-05
EP3930722A4 (en) 2022-12-28
JP2022521955A (ja) 2022-04-13
JP7578602B2 (ja) 2024-11-06

Similar Documents

Publication Publication Date Title
US12485125B2 (en) Treatment with P2X3 modulators
US7169797B2 (en) Protein-tyrosine phosphatase inhibitors and uses thereof
JP2022547617A (ja) Ｉｌ－１７ａモジュレーターおよびその使用
US20040167188A1 (en) Protein-tyrosine phosphatase inhibitors and uses thereof
CA3076150A1 (en) Selective p2x3 modulators
US20240299404A1 (en) Treatment of pruritus with p2x3 modulators
HUP0303624A2 (hu) NEP inhibitor hatású N-fenpropil-ciklopentil-csoporttal szubsztituált glutáramid származékok és ezeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására
US20200148681A1 (en) Crystalline spirocyclic compound, a dosage form containing, a method for using in treatment of disease, and a method for recrystallizing
CA3170664A1 (en) P2x3 modulators
JPH0267282A (ja) 四環式ケトン
JP2022527916A (ja) アンドロゲン受容体のｎ末端ドメインの阻害剤
KR20210120020A (ko) Magl 저해제에 의해 질병을 치료하는 방법
GB2201676A (en) Piperazinecarboxylic acid, its preparation and pharmaceutical compositions containing it
JP4781362B2 (ja) ４級アンモニウム基を有するキヌクリジン化合物とその調製方法、およびアセチルコリン遮断剤としての用途
EP3935059A1 (en) Modulators of ampa receptor signaling
WO2014181101A1 (en) 2-acyl-4-oxy-1,2-dihydropyrrol-5-one compounds for improving memory and cognitive function
JPH0710851A (ja) アミノアルコール誘導体及びその用途
HUP0501212A2 (en) Optical isomers of dihydro-2,3-benzodiazepin, their stereoselective synthesis, pharmaceutical compositions containing them and their use

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240607